Lantern Pharma Completes Japan Enrollment for Phase II LP-300 NSCLC Trial Ahead of Schedule

Clinical TrialsTherapueticsFDA
Written By Corey Hubbard
Audio Block
Double-click here to upload or link to a .mp3. Learn more

GlassBury Cares Podcast

Episode #31

Corey Hubbard
Previous

Pfizer's Sickle Cell Strategy Stumbles: Inclacumab Fails Phase III Oxbryta Withdrawn
Next

Brain Breakthrough: Oragenics and Southern Star Pioneer New Hope for Concussion Treatment